Published in Indian J Nephrol on April 01, 2008
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr (1999) 2.79
Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med (1993) 1.50
Treatment of hyperlipidemia in nephrotic syndrome: time for a change? Nephron (1992) 1.41
Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem (2000) 1.36
Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol (1996) 1.24
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia (1995) 1.06
Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs (1991) 1.04
Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol (2005) 1.03
Lipid-lowering therapy in patients with renal disease. Kidney Int (1995) 0.96
Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits. J Nutr Biochem (2003) 0.95
Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil (2007) 0.87
Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron (2002) 0.86
Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism (1990) 0.84
Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis. Am J Med (2000) 0.82
Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol (1994) 0.81
Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant (1992) 0.80
Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract Suppl (1996) 0.80
Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. J Nephrol (2002) 0.78
Rheumatic manifestations of hyperlipidemia and antihyperlipidemia drug therapy. Semin Arthritis Rheum (1993) 0.78
Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Am J Nephrol (1999) 0.78
Safety profile of fluvastatin. Br J Clin Pract Suppl (1996) 0.78
Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol (1993) 0.77
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]. Therapie (1994) 0.77
Hyperlipidaemia of the nephrotic syndrome--the search for a nephrotic factor. Nephrol Dial Transplant (1995) 0.77
Lipids--what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant (1995) 0.77
Neuromuscular toxicity in nephrotic patients treated with fluvastatin. J Nephrol (2002) 0.77
Hepatitis C virus infection in chronic haemodialysis patients, a clinicopathologic study. Nephrol Dial Transplant (1992) 1.40
Colchicine could be safely used in renal patients. Nephrol Dial Transplant (1997) 1.06
Prevalence of hantavirus antibody in patients with chronic renal disease in Egypt. Trans R Soc Trop Med Hyg (2004) 1.03
Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis (2011) 0.89
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Plasmonic band gaps and trapped plasmons on nanostructured metal surfaces. Phys Rev Lett (2005) 0.84
Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant (2013) 0.84
Paroxysmal nocturnal hemoglobinuria and renal failure. Saudi J Kidney Dis Transpl (2008) 0.79
Easily coupled whispering gallery plasmons in dielectric nanospheres embedded in gold films. Phys Rev Lett (2006) 0.78
The effect of extracorporeal high blood flow rate on left ventricular function during hemodialysis--an echocardiographic study. Clin Cardiol (1993) 0.78
Cardiovascular drug trials: how to examine interaction, and why so. Neth Heart J (2007) 0.78
High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience. Bone Marrow Transplant (2008) 0.77
Alterations of plasma free amino acids in nephrotic syndrome. Int Urol Nephrol (1994) 0.77
High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant (2009) 0.77
Treatment of a severe extensive cutaneous chronic GVHD after allo-HSCT using glycerolyzed skin allografts and cultured epidermis from the same donor. Bone Marrow Transplant (2010) 0.77
Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. Bone Marrow Transplant (2012) 0.76
The impact of haemodialysis-associated variables on lipid profile in Egyptian haemodialysis population. Int Urol Nephrol (2007) 0.76
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant (2007) 0.76
Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis. Nephrol Dial Transplant (1992) 0.76
Diffuse large B-cell lymphoma transformed from mucosa-associated lymphoid tissue lymphoma arising in a female urethra treated with rituximab for the first time. Case Rep Oncol (2012) 0.75
Cyclosporine Neoral in renal transplant recipients: impact on hepatic dysfunction. Transplant Proc (1997) 0.75
Study of malignancy among Egyptian kidney transplant recipients. Transplant Proc (1997) 0.75
[Not Available]. Rev Chir Orthop Reparatrice Appar Mot (2005) 0.75
Study of morphologic risk factors in graft biopsies from patients with living related donor kidney transplants. Am J Nephrol (1996) 0.75
Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against hla in highly sensitized transplant candidates. Transplant Proc (2004) 0.75
Living-related-donor kidney transplantation outcome in recipients with primary focal-segmental glomerulosclerosis. Am J Nephrol (1999) 0.75
Study of effect of optimization of dialysis and protein intake on neuromuscular function in patients under maintenance hemodialysis treatment. Am J Nephrol (1998) 0.75
Anticardiolipin antibodies in children on chronic haemodialysis. Nephrol Dial Transplant (1994) 0.75
Effect of liver disease in kidney transplant recipients on cyclosporine dose and metabolite levels. Transplant Proc (1994) 0.75
Heme biosynthesis and porphyrin studies in chronic renal failure patients following kidney transplantation. Int Urol Nephrol (1991) 0.75